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Introduction
Genome-wide association studies (GWAS) are based
on the “common disease, common variant” assump-
tion, which means that the genetic risk for a common
disease is mostly attributable to a relatively small num-
ber of common genetic variants [1–4]. GWAS have
only recently become practical after three key tools
have been made available: the discovery of more than
10 million single nucleotide polymorphisms (SNPs) 
in the human genome (http://www.ncbi.nlm.nih.gov/
SNP), the HapMap (http://www.hapmap.org) that mea-
sures the degree of association between the alleles of
neighboring SNPs, and high-throughput genotyping
platforms [5].
GWAS use high-throughput genotyping technology
to relate hundreds of thousands of genetic markers to
clinical conditions and measurable traits [1], with the
expectation that systematic study of DNA variations
throughout the genome in relation to a disease may lead
to localization of the causal genes [3]. GWAS rely on 
a nonrandom association called linkage disequilibrium
(Table 1) [6]. Contrary to the traditional hypothesis-
driven research, GWAS are unconstrained by prior
hypotheses regarding genetic associations with disease.
Hence, GWAS represent an important step beyond
candidate gene studies [1].
Case-control association studies, the most common
type of GWAS, detect nonrandom co-occurrences be-
tween alleles (genotypes) and traits (phenotypes) [7].
Genotypes can be defined by many types of genetic
markers, including SNPs, microsatellites, minisatellites
and copy number variations (Table 1) [1,2,8–10]. SNPs
are the preferred genetic markers for GWAS because 
of their abundance; about 12 million unique human
SNPs have been assigned a reference SNP number in
the National Center for Biotechnology Information’s
SNP database [10]. Recently, copy number variation
polymorphisms have attracted researchers’ attention
because of their ubiquity and potential dosage effects
on gene expression (Table 1) [11].
MacArthur praised GWAS, saying that “for the first
time in human history, we have the power to identify the
precise genetic differences between human beings that
contribute to variation in disease susceptibility” [4].
A GENOME-WIDE ASSOCIATION STUDY
PRIMER FOR CLINICIANS
Tzu-Hao Wang1,2,3, Hsin-Shih Wang1,4*
1Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and Chang Gung University, 2Genomic Medicine
Research Core Laboratory, Chang Gung Memorial Hospital, 3Graduate Institute of Basic Medical Sciences, and 
4Graduate Institute of Clinical Medical Sciences, Chang Gung University, Tao-Yuan, Taiwan.
SUMMARY
Genome-wide association studies (GWAS) use high-throughput genotyping technology to relate hundreds 
of thousands of genetic markers (genotypes) to clinical conditions and measurable traits (phenotypes). This review
is intended to serve as an introduction to GWAS for clinicians, to allow them to better appreciate the value and
limitations of GWAS for genotype-disease association studies. The input of clinicians is vital for GWAS, since
disease heterogeneity is frequently a confounding factor that can only really be solved by clinicians. For diseases that
are difficult to diagnose, clinicians should ensure that the cases do indeed have the disease; for common diseases,
clinicians should ensure that the controls are truly disease-free. [Taiwan J Obstet Gynecol 2009;48(2):89–95]
Key Words: copy number variation, genome-wide association studies, genotype, linkage disequilibrium, 
phenotype, single nucleotide polymorphisms
*Correspondence to: Dr Hsin-Shih Wang, Depart-
ment of Obstetrics and Gynecology, Chang Gung
Memorial Hospital and Chang Gung University, 5,
Fu-Shin Road, Gwei-Shan, Tao-Yuan 333, Taiwan.
E-mail: hswang@cgmh.org.tw
Accepted: April 29, 2009
Above the public excitement from the media and pro-
fessional enthusiasm from academia, we need sufficient
genomic knowledge to understand the results of GWAS.
This review is not intended to exhaustively cover all
reports of GWAS; instead, it aims to provide an intro-
duction for clinicians to enable them to appreciate the
values and limitations of GWAS as genotype–phenotype
association studies.
GWAS in Complex Diseases
Several GWAS of complex human diseases (Tables 2
and 3) have recently been performed using the newly
completed sequencing of the human genome [12] and
the haplotype mapping of human SNPs [13,14]. In 2007
alone, GWAS were used to identify the risk loci for type
1 diabetes [15], type 2 diabetes [16–19], breast cancer
[20–22], prostate cancer [23–25], myocardial infarction
[26], atrial fibrillation [27], and autoimmunity [28]
(Table 2). All of these papers were published in Science
and Nature series journals.
Other GWAS results have been published in the
New England Journal of Medicine from 2007 to 2008. The
New England Journal of Medicine is the most rigorously
reviewed and well-esteemed clinical journal, and their
publication of GWAS results is indicative that such stud-
ies are considered to be of tremendous relevance to
clinical medicine today. Risk loci in the human genome
have been identified for coronary artery disease [29],
sporadic amyotrophic lateral sclerosis [30], multiple
sclerosis [31], rheumatoid arthritis and systemic lupus
erythematosus [32], rheumatoid arthritis [33], autism
[34], prostate cancer [35], asthma [36], neuroblastomas
[37], and statin-induced myopathies [38] (Table 3).
The discovery of the gene regions associated with
type 2 diabetes best demonstrates the strength of GWAS
[39]. The identification of the disease genes for type 2
diabetes was regarded as “the geneticist’s nightmare”
[39]. This is because for more than a decade, geneti-
cists devoted enormous efforts to candidate gene stud-
ies and international linkage consortia in attempts to
find type 2 diabetes genes, but only obtained evidence
for common variants in four genes, KCNJ11 [40,41],
PPARG [42], TCF2 [24], and WFS1 [43]. In 2007, how-
ever, six GWAS reported evidence for six new “gene
regions” that may be involved in type 2 diabetes (Table
2) [16–19,44,45]. The closest genes to these regions are
HHEX-IDE, SLC30A8, CDKAL1, CDKN2A-2B, IGF2BP2,
and FTO. The fast pace of GWAS suggests that re-
searchers will soon be able to simply look up case-control
results for any common disease on the Web [39].
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Table 1. Glossary of published genome-wide association studies
Term Definition Reference
Alleles Alternate forms of a gene or chromosomal locus that differ in 1
DNA sequence.
Copy number polymorphism A copy number variation that occurs in more than 1% of the population. 8
Copy number variation A DNA segment of at least 1,000 bp (1 kb) in size, for which copy number 8
differences are observed in the comparison of two or more genomes.
Genome-wide association A type of phenotype–genotype association study conducted at the 1
study scale of the genome, usually using hundreds of thousands of markers 
of genetic variation.
Genotype Any type of genetic variation. The most useful markers are single 2
nucleotide polymorphisms, microsatellites, and copy number 
polymorphism markers.
Linkage disequilibrium Association between two alleles located so near each other that they 1
are inherited together more frequently than expected by chance.
Microsatellites The length of the repeating unit is less than 10 bp. 9
Minisatellites The length of the repeating units is from 10 to 100 bp. 9
Phenotype A trait, including the disease to be studied. 2
Single nucleotide  The smallest genomic variation is the change in a single nucleotide. 10
polymorphism When the single nucleotide variation occurs in more than 1% of 
the population, it is called a single nucleotide polymorphism.
Variable number tandem Also called short tandem repeats, including microsatellites and 9
repeats minisatellites.
Study Designs and Strategies for GWAS
Detailed instructions for conducting a sound GWAS
are beyond the scope of this introductory review, and
readers who plan to perform their own GWAS are
encouraged to read the comprehensive reviews that
address the rationale [46], data analysis [47], biosta-
tistical aspects [48], and interpretation [1] of GWAS.
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Table 2. Genome-wide association study reports in the Nature series and Science in 2007
Independent 
Disease Authors Journal Analytical platforms replication 
studies
Atrial fibrillation Gudbjartsson et al [27] Nature Illumina Yes
Autoimmunity Burton et al [28] Nature Illumina Yes
Genetics
Breast cancer Stacey et al [20] Nature Illumina Yes
Genetics
Hunter et al [21] Nature Illumina Yes
Genetics
Easton et al [22] Nature Affymetrix Yes
Diabetes, type 2 Saxena et al [16] Science Affymetrix Yes
Zeggini et al [17] Science Affymetrix Yes
Scott et al [19] Science Illumina Yes
Sladek et al [18] Nature Illumina and Sequenom No
Steinthorsdottir et al [44] Nature Illumina Yes
Genetics
Myocardial infarction Helgadottir et al [26] Science Illumina Yes
Prostate cancer Yeager et al [23] Nature Illumina Yes
Genetics
Gudmundsson et al [24] Nature Illumina Yes
Genetics
Seven diseases* Wellcome Trust Case Nature Affymetrix No
Control Consortium [45]
*Bipolar disorder, coronary disease, Crohn’s disease, hypertension, rheumatoid arthritis, and type 1 and type 2 diabetes.
Table 3. Genome-wide association study reports in the New England Journal of Medicine (2007–2008)
Disease Authors (yr) Analytical platforms
Independent replication 
studies
Asthma and lung function Ober et al (2008) [36] Affymetrix Yes
Autism Weiss et al (2008) [34] Affymetrix Yes
Coronary artery disease Samani et al (2007) [29] Affymetrix Yes
Multiple sclerosis Hafler et al (2007) [31] Affymetrix Yes
Neuroblastoma Maris et al (2008) [37] Illumina Yes
Prostate cancer Zheng et al (2008) [35] Sequenom MassArray This study is a 
replication itself
Rheumatoid arthritis Plenge et al (2007) [33] Illumina Yes
Rheumatoid arthritis and Remmers et al (2007) [32] Illumina Yes
systemic lupus erythematosus
Sporadic amyotrophic lateral Dunckley et al (2007) [30] Affymetrix and Illumina Yes
sclerosis
Statin-induced myopathy Link et al (2008) [38] Illumina Yes
Furthermore, a working group organized by the National
Cancer Institute and the National Human Genome
Research Institute of the United States [2] has recently
addressed three topics: (1) assessment of the validity
and limitations of any genetic association study, (2)
criteria for establishing replication in genetic associ-
ation studies, and (3) points to consider for publica-
tion of sound genotype–phenotype association reports.
Chanock et al [2] summarized criteria both for evalu-
ating the soundness of an initial association report
and for establishing positive replication in a checklist
format.
GWAS can follow case-control, cohort or trio
designs [1]. Case-control studies are by far the most
commonly used for GWAS, and include all the studies
listed in Tables 2 and 3. The most obvious advantage
of the case-control study design is that large numbers
of case and control participants can be recruited in 
a short time frame. However, this design is prone to
biases that are mainly caused by population stratifica-
tion (discussed later in the “Limitations of GWAS” sec-
tion). In cohort studies, such as the Women’s Genome
Health Study [49] or Framingham Heart Study [50], 
a large number of participants with extensive baseline
information are followed up to detect the incidence 
of disease development throughout the study period,
which is usually decades. Some participants develop
disease during the observation period, and thus the
disease risk can be estimated [36]. The cohort design
is free of survival bias, but its apparent disadvantage 
is the expense of a lengthy follow-up period. The trio
design enrolls the affected participant and both of his/
her parents, in order to study linkage disequilibrium of
the disease and genetic markers [51]. The trio design is
not affected by genetic differences between case and
control participants (unrelated to disease or population
stratification), but it can be difficult to recruit both
parents and the diseased offspring in disorders with
older ages of onset [1]. Ober et al [36] applied both
case-control and cohort designs to identify potential
serum biomarkers for asthma.
The two-stage approach for GWAS is a common
strategy that maximizes statistical power while still
maintaining reasonable costs [1,52]. In the first stage,
complete panels of genetic markers (e.g. 500,000 SNPs
or more) are screened for a fraction of samples (e.g. 500
cases and 500 controls) to identify groups of markers
that reach a threshold of statistical significance, e.g.
p < 10−7. In the second stage, only the groups of genetic
markers shown to be potentially associated with the
disease in the first stage are further genotyped across all
the recruited case and control participants (e.g. 3,000–
10,000 cases and the same numbers of controls).
Furthermore, a three-stage strategy has been proposed:
(1) in stage one, 400 cases and 400 controls are geno-
typed for 500,000 SNPs; (2) in stage two, 4,000 cases
and 4,000 controls are genotyped for 25,000 SNPs;
and (3) in stage three, 20,000 cases and 20,000 con-
trols are genotyped for 25 SNPs [1]. However, thanks
to the advent of new versions of microarrays, such as
Affymetrix SNP array 6.0 (Affymetrix Inc., Santa Clara,
CA, USA) with 1.8 million genetic markers on a single
microarray but with a lower cost per microarray than
previous chips, we have a better platform to use for
genotyping the whole sample population using the
same microarray platform, i.e. the one-stage approach.
Genotyping Platforms for GWAS
Exponential improvements in analytic platforms, in terms
of both hardware and software, are among the driving
factors behind the dramatic discovery of genome-wide
gene-disease associations. For GWAS with SNP and
copy number polymorphism markers [34,53], both
Affymetrix (http://www.affymetrix.com) and Illumina
(http://www.illumina.com) microarray systems have
been used successfully (Tables 2 and 3). In 2006, Barrett
and Cardon [54] evaluated the first generation of these
high-throughput platforms and concluded that both
offered similar levels of genome coverage.
If the goal of GWAS is to identify the SNPs that
account for amino acid changes in disease-related genes,
i.e. nonsynonymous SNPs, then both Illumina [28] and
Affymetrix coding SNP 10K can be used. To perform
replication studies on a limited number of preselected
genetic markers, mass spectrometry genotyping (e.g.
Sequenom MassArrays [Sequenom, San Diego, CA,
USA]) [35] and real-time quantitative polymerase chain
reaction (PCR) genotyping (e.g. TaqMan technology
[Applied Biosystems, Foster City, CA, USA]) may be
less expensive than entire-genome microarrays. Another
PCR-based platform, Dynal RELI SSO assay (Dynal
Biotech Ltd., Bromborough, UK) has been used to ana-
lyze 1,729 SNPs and to localize type 1 diabetes suscep-
tibility to the major histocompatibility complex class I
genes, HLA-B and HLA-A [15].
Limitations of GWAS
Potential limitations of GWAS include: (1) false-positive
and false-negative results, (2) insensitivity to rare vari-
ants and structural variants, (3) requirement for large
sample sizes, (4) genotyping errors, (5) lack of infor-
mation on gene function, and (6) possible biases due
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to inappropriate selection of cases and controls [1].
Possible solutions for these limitations are suggested
below.
A larger sample size will overcome the first three
limitations. Confirmation of gene-disease association
in replication studies is currently mandatory [2]. The
sample size for the discovery of gene regions in a com-
mon disease such as type 2 diabetes is proposed to be
> 10,000 cases and controls [39]. Regarding the limi-
tation of genotyping errors, dramatic advancements 
in analytical technology will eventually resolve geno-
typing errors. Currently, confirmation of critical SNPs
using other technology is advised, such as real-time
PCR or mass spectrometry genotyping. For the fifth
limitation, GWAS are intended to identify associations
between candidate genomic loci, or gene regions (rather
than actual genes), and a disease [39]. After a disease-
associated region has been confirmed in replication
studies, whether or not the genes within the region really
cause the disease should be examined using cell culture
systems and/or animal models that have knock-out or
knock-in genes [55].
Two groups of biases can confound GWAS results:
population stratification and disease heterogeneity.
Population stratification, also called population sub-
structure, is caused by differences in allele frequency
between cases and controls due to systematic ancestral
differences that are defined by ethnicity or geographic
origin [56]. Population stratification-related variations
in allele frequencies may cause differences in disease risk,
which, in turn, falsely identify the subgroup-associated
genes as being disease-related [1]. To avoid this bias,
attention should be paid to ensure that the distribu-
tion of risk factors of interest in controls is the same as
that in the diseased cases [57]. Disease heterogeneity,
on the other hand, frequently makes the classification
of case participants less straightforward than expected.
Technology and geneticists have to rely on clinicians to
weed out false-positives and false-negatives. For dis-
eases that are difficult to diagnose, clinicians should
ensure that the cases do indeed have the disease;
whereas for common diseases, clinicians should ensure
that the controls are truly disease-free [1].
Concluding Remarks
Given the abundance of genetic association studies
(Tables 2 and 3), we doubt the need to plan new initial
genetic association or replication studies. To address
this, the first step is to carry out a comprehensive liter-
ature review of the phenotype. If the selected pheno-
type has not previously been convincingly studied, and
we have sufficient numbers of subjects with an unam-
biguous and relatively homogenous phenotype, we are
in a good position to perform an initial genetic asso-
ciation study. In considering the need for replication
studies, it is important to remember that evaluations
of an association in populations with different ances-
tries from that of the initial report are acutely needed,
considering that genomic variation is greater across
populations [2]. Most genetic association studies have
been conducted in Caucasians, rather than in individ-
uals of Asian or Chinese ethnicities. Therefore, replica-
tion studies in Chinese populations, which validate the
initial genetic association for the phenotype, would
greatly increase our confidence regarding the initial
genotype–phenotype association.
When an independent replication study is planned,
the selection criteria for the SNPs to be replicated 
from the initial study include an estimated large effect
of the reported loci (> 2 is the optimum suggested by
Chanock et al [2]), a low p value in linkage-disequilibrium
calculations, and that supporting results of those SNP
have been reported. Additionally, SNPs to be further
verified should be selected after considering their puta-
tive functional correlations. Validation of such SNPs not
only confirms the significance of previously reported
phenotype–genotype associations (despite genomic
variations among different ethnicities), but also pro-
vides insight into our understanding of diseases, so
helping us to develop new testable experiments to dis-
cover the biologic and molecular mechanisms behind
the diseases.
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